Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Once-daily tacrolimus extended release formulation: Experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients TRANSPLANTATION Florman, S., Alloway, R., Kalayoglu, M., Punch, J., Bak, T., Melancon, J., Klintmalm, G., Busque, S., Charlton, M., Lake, J., Dhadda, S., Wisemandle, K., Wirth, M., Fitzsimmons, W., Holman, J., First, M. R. 2007; 83 (12): 1639-1642

Abstract

Compliance with complex immunosuppressant drug therapies in transplant recipients might be improved with regimens that require less frequent dosing. A once-daily extended release (XL) formulation of tacrolimus has been developed that allows a 1:1 conversion from the twice-a-day tacrolimus (TAC) formulation and has a good exposure to trough concentration correlation. In an open-label, multicenter study, stable liver transplant recipients (n=69) were converted from twice-a-day TAC to XL once-daily in the morning, and were maintained for at least 2 years postconversion using the same therapeutic monitoring and patient care techniques employed with TAC. Two years after conversion, the incidence of biopsy-confirmed acute rejection was 5.8% (4 of 69); patient and graft survival was 98.6% (68 of 69). The safety profile of XL was consistent with that previously reported for TAC. Liver transplant recipients can be converted from twice-a-day TAC to once-daily XL and maintained for at least 2 years postconversion with neither unique efficacy nor safety concerns.

View details for DOI 10.1097/01.tp.0000265445.09987.f1

View details for Web of Science ID 000247578200019

View details for PubMedID 17589349